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Abstract: Cancer cachexia is a severe wasting syndrome characterized by the progressive loss of lean body mass and 
systemic inflammation. Up to 80% of cancer patients experience cachexia, with 20-30% of cancer-related deaths 
directly linked to cachexia. Despite efforts to identify early cachexia and cancer relapse, clinically useful markers are 
lacking. Recently, we identified the role of muscle-specific ubiquitin ligases Atrogin-1 (MAFbx, FBXO32) and Muscle 
Ring Finger-1 in the pathogenesis of cardiac atrophy and hypertrophy. We hypothesized that during cachexia, the 
Atrogin-1 and MuRF1 ubiquitin ligases are released from muscle and migrate to the circulation where they could 
be detected and serve as a cachexia biomarker. To test this, we induced cachexia in mice using the C26 adeno- 
carcinoma cells or vehicle (control). Body weight, tumor volume, and food consumption were measured from inocu-
lation until ~day 14 to document cachexia. Western blot analysis of serum identified the presence of Atrogin-1 and 
MuRF1 with unique post-translational modifications consistent with mono- and poly- ubiquitination of Atrogin-1 and 
MuRF1 found only in cachectic serum. These findings suggest that both increased Atrogin-1 and the presence of 
unique post-translational modifications may serve as a surrogate marker specific for cachexia. 
Keywords: Cancer cachexia, biomarkers, muscle ring Finger-1, Atrogin-1, TRIM63, FBXO32
Introduction
Cancer cachexia is a common finding in patients 
with cancer, experienced as a marked unin-
tended weight loss, sarcopenia, anorexia, and 
fatigue [1]. The metabolic changes are distinct 
from starvation, reduced caloric intake, or 
tumor alone [2]. It’s estimated that ~1.5 million 
people in the United States experience cancer 
cachexia each year, with those resulting from 
gastrointestinal, head and neck, lung, and pro- 
state solid tumors most affected by cachexia 
(as recently reviewed) [1]. Cachexia is often an 
early finding in cancer and cancer recurrence, 
with detrimental effects on a patient’s function, 
quality of life (QOL) measures, and has conse-
quences such as immobility and cardiac/respi-
ratory failure [3, 4]. The common clinical find-
ings of cachexia include anorexia or reduced 
nutritional intake, a systemic inflammatory 
response, decreased muscle strength and 
fatigue [5, 6]. In addition to these three find-
ings, biochemical alterations such as anemia, 
evidence of ongoing inflammatory response, 
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and low albumin have been proposed as mark-
ers [7]. However, these criteria and biochemical 
markers lack sensitivity and specificity and do 
not generally identify cachexia until later in the 
pathophysiology of the disease, when physical 
symptoms can be obvious. 
Recently, the molecular mechanisms underly-
ing skeletal muscle and cardiac atrophy have 
begun to be elucidated. As early as 1997, the 
role of the ubiquitin proteasome system in 
muscle atrophy was evident, with proteasome 
inhibition reducing the experimental skeletal 
muscle atrophy [8]. Later, identification of two 
muscle-specific ubiquitin ligases (E3s) play an 
important role in understanding the molecular 
mechanisms of skeletal muscle atrophy [9] and 
later cardiac atrophy [10]. These initial studies 
demonstrated that the lack of these E3s 
(MuRF1 and Atrogin-1) could significantly pre-
vent muscle atrophy [9, 10]. After three days of 
unilateral lower limb suspension and limb 
immobilization, increases in Atrogin-1 and Mu- 
RF1 were identified in human biopsies [11]. Si- 
milarly, after immobilization in humans leads to 
increases in skeletal muscle Atrogin-1 and 
MuRF1 [12]. In humans receiving an LVAD (left 
ventricular assist device) to unload the heart as 
a bridge to transplant, elevations in both Atrogin 
1 [13] and MuRF1 [10] have been identified.
Recent studies have identified the presence 
of circulating muscle-specific Atrogin-1 and 
MuRF1 by ELISA in both rats and humans [14]. 
In the present study, we sought to determine 
the character and quantity of circulating 
Atrogin-1 and MuRF1 using an established 
cancer mouse model from two independent 
laboratories as a possibly novel biomarker of 
cachexia.
Materials and methods
Animals, cachexia model, and human studies 
Eight-week-old BALB/c mice (Charles River 
Laboratories (Wilmington, MA) and CD2F1 mice 
(Harlan Laboratories, Indianapolis, IN) were 
obtained and acclimated for a minimum of 10 
days. Cohort 1 (Serum collected): Cancer cac- 
hexia was induced in BALB/c mice by subcuta-
neous (s.c.) injection of 0.5 × 106 C26 adeno-
carcinoma cells (or PBS vehicle control) in the 
right flank in 100 microL sterile PBS (Cohort 1, 
N=3 Control, N=6 Experimental biological repli-
cates). Cohort 2 (platelet-poor plasma collect-
ed): Cancer cachexia was induced in CD2F1 
mice (n=5) by s.c. injection of 1 × 106 C26 ade-
nocarcinoma cells intrascapularly (or saline 
vehicle control). Mice were bled prior to euth- 
anasia on Day 17 by retro-orbital bleeding 
(Cohort 1) and Day 14 (Cohort 2) by cardiac 
puncture, as previously described [15-17]. Tu- 
mor volume measurements, body weight and 
food/water intake were assessed weekly until 
last time point, as previously described [15, 
18]. All mouse experiments, housing, and euth- 
anasia were approved by the Institutional 
Animal Care and Use Committees (IACUC) re- 
view boards at the University of North Carolina 
(Cohort 1) and Indiana University (Cohort 2) 
and complied with National Institutes of Health 
Guidelines for Use and care of Laboratory 
Animals and with the ethical standards laid 
down in the 1964 Declaration of Helsinki and 
its later amendments. Use of the human plas-
ma used in this study was approved by the 
University of North Carolina Institution Review 
Board (No. 05-2659; formerly 05-SURG-1224-
ORC) and collected on Oncology protocol LCCC 
0612 (Metabolomic analysis of cachexia in 
head and neck cancer patients). Use of the 
human heart tissue used in this study was 
approved by the University of North Carolina 
Institution Review Board (No. 03-1359). 
Serum, plasma, and platelet-poor plasma 
(PPP) collection
Mouse serum: On Day 17 just prior to euthana-
sia ~200 microliters of whole blood was col-
lected via retro orbital bleed directly into pedi-
atric serum separator tubes with clot activator 
(Cat.#367983, Becton Dickinson and Co., 
Franklin Lakes, NJ). Blood was incubated at RT 
for 1 h, centrifuged for 10 minutes at 1300 × g, 
before serum was collected and immediately 
stored at -80°C. Mouse PPP: On Day 14, upon 
euthanasia, platelet-poor plasma (PPP) was 
prepared from blood collected by cardiac punc-
ture and placed on ice in EDTA microtainers, fol-
lowed by centrifugation at 1,000 × g for 15 min, 
removal of the plasma, and a second centrifu-
gation at 10,000 × g for 10 min at 4°C, as previ-
ously described [19]. Mouse serum and mouse 
PPP stored at -80°C until analyzed by immu-
noblot. Human pooled serum and plasma were 
stored at 4°C until analyzed by immunoblot.
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Immunoblot detection of circulating mouse 
Atrogin-1 and MuRF1 
Diluted mouse serum samples (1:400 final dilu-
tion) were denatured in NuPAGE LDS Sample 
Buffer with reducing agent (Cat.#NP0007 and 
Cat.#NP0004, Thermofisher Scientific, Inc.) at 
70°C for 10 min and resolved on a 4-12% 
NuPage Bis-Tris gradient gel (Cat.#NP0322, 
Thermofisher Scientific, Inc.) along with mo- 
lecular weight standards (Cat.#10748-010, 
ThermoFisher, Inc., Waltham, MA) at 200V for 
45 min, then transferred onto PVDF membrane 
in 20% MeOH MES run buffer with 200V for 
120 min. An anti-Atrogin-1 (Cat.#sc-33782 
H-300, Rabbit polyclonal 1:500 in 1% Milk, 
Santa Cruz Biotechnology, Inc., Dallas, TX) was 
incubated with the membrane for 1 hr at RT, 
washed 3X with TBST, then incubated with an 
HRP-conjugated anti-rabbit antibody (Cat.#- 
NA934, 1:4000 in 5% Milk, GE Healthcare Life 
Sciences, Pittsburg, PA). PVDF membranes 
were washed 4 times (10 min each) with TBST, 
developed using the ECL™ Plus (GE Healthcare; 
Pittsburgh, PA), then visualized by exposure to 
Amersham Hyperfilm ECL™ (GE Healthcare; 
Pittsburgh, PA) and developed using a Konica 
Medical Film Developer (Exposure time ~3 min, 
Cat.#SRX-101A, Konica Minolta Medical and 
Graphic Inc., Wayne, NJ). Film images were digi-
tized with a ScanMaker 9800XL TMA 1600 
(Cat.#MRS-3200A3, Microtek, Grove, IL), ex- 
ported as 300 DPI TIFF files (pixels: 1084 
width, 920 height), and inverted in Photoshop 
(CS6, Ver. 13.0 x64, Adobe, San Jose, CA) for 
densitometric analysis. Quantitative densito-
metric analysis of ECL images was performed 
using ImageJ 1.50 g software for Mac (for film-
derived TIFF images, NIH, Bethesda, MD) [20]. 
Diluted mouse platelet-poor plasma samples 
(1:25) were denatured in NuPAGE LDS Sample 
Buffer with reducing agent (Cat.#NP0007 and 
Cat.#NP0004, Thermofisher Scientific, Inc.) at 
65°C for 10 min and resolved in parallel with 
molecular weight standards (Cat.#LC5602, 
In-vitrogen, Carlsbad, CA) on a 4-12% gradient 
Bis-Tris gel (Cat.#NP0322, Thermofisher Sci- 
entific, Inc.) by applying 200 V for 35 min in 
MES SDS running buffer (Cat.#NP0002, The- 
rmofisher Scientific, Inc.). Proteins were trans-
ferred from Bis-Tris gel onto PVDF using the 
NuPAGE transfer buffer (Cat.#NP0006, The- 
rmofisher Scientific, Inc.) with 20% MeOH at 30 
V for 66 min. The PVDF membrane was blocked 
for 1 hr at RT in 5% dry milk in TBS with 0.1% 
Tween-20 (TBST) prior to overnight immunob- 
lot with anti-Atrogin-1 (Cat.#sc-33782 H-300, 
Rabbit polyclonal 1:500 in 1% Milk, Santa Cruz 
Biotechnology, Inc., Dallas, TX) or anti-MuRF1 
(Cat.#sc-27642 C-20, Goat polyclonal 1:200 in 
5% BSA, Santa Cruz Biotechnology, Inc., Dallas, 
TX) at 4°C. Membranes were washed 3 times 
(10 min each) in TBST, incubated a secondary 
HRP-labeled anti-rabbit (Cat.#A9169, 1:15,000 
in 1% Milk, Sigma-Aldrich, St. Louis, MO) or 
HRP-labeled anti-goat (Cat.#A4174, 1:10,000 
in 5% BSA, Sigma-Aldrich, St. Louis, MO) for 1 
hr at RT, washed 4 times (10 min each) with 
TBST, and developed using the ECL + Plus 
Western Blotting system (Cat.#RPN2132, GE 
Healthcare Life Sciences, Pittsburg, PA). 
Immunoblot signal was visualized using an 
Ultra-Violet Products (UVP) BioSpectrum Ima- 
ging SystemTM (Cat.#81-0346-01 rev d, UVP, 
Ltd., Upland, CA) with VisionWorksLS Soft- 
ware (Version 8.5.15064.8534, UVP, Ltd.). 
Quantitative densitometric analysis of ECL 
images was performed using VisionWorksTM LS 
(for UVP-captured images, UVP, Ltd.) [21]. Dil- 
uted human plasma samples and pooled serum 
sample. 7.5 microliters of 1:400 human plasma 
and diluted pooled serum was run per lane in 
LDS with reducing 10X DTT. Samples were run 
on 12 well 4-12% gradient Bis-Tris gel and 
transferred onto PVDF, as described above. The 
membrane was blocked in 5% milk, then immu-
noblotted with either: 1) anti-MuRF1 (1:1000 in 
TBS-T overnight at 4°C, Novus Biologicals Ab, 
Cat.#nb100-2406, Novus Biologicals, LLC), 
followed by an anti-goat antibody (1:10,000 in 
5% milk for 1 hr at room temperature, Cat.#sc- 
2768, Santa Cruz Biotechnology); or 2) anti-
Atrogin-1 (1:500 in 1% milk in TBST overnight 
at 4°C, Cat.#sc-33782 H-300, Santa Cruz 
Biotechnologies), followed by an anti-rabbit 
1:4,000 (5% milk for 1 hr at room tempera- 
ture, Cat#NA934, Amersham Biosciences, GE 
Healthcare). The human pooled serum was also 
assayed for CHIP using goat anti-CHIP (Millipore, 
cat.no. AB10000), followed by an anti-goat anti-
body (Cat.#sc-2768, Santa Cruz Biotechnology) 
and included human heart lysates controls 
loaded 10-50 micrograms per lane.
Statistical analyses
All data were subject to statistical analysis per-
formed using two-tailed Student’s t-test, with 
significance defined as p<0.05. All results are 
presented as the mean ± SEM. Data was ana-
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lyzed using Microsoft Excel for Mac 2011 
(Version 14.6.3, Redmond, WA) and Prism for 
Mac (Version 7.0, GraphPad, Inc., San Diego, 
CA) for all analyses performed.
Results
Two independent mouse models of cachexia 
were studied here using the C26 carcinoma 
cancer cachexia model. In the first, 0.5 × 106 
C26 carcinoma cells were injected subcutane-
ously (s.c.) into the right flank of BALB/c mice, 
where the tumors developed until day 17, when 
we collected serum. In the second model, 106 
C26 carcinoma cells were injected s.c. between 
their scapula, where tumors developed until 
day 14, when platelet-poor plasma was collect-
ed. The collected serum and plasma were then 
analyzed by immunoblot analysis for the pres-
ence of the muscle-specific ubiquitin ligases 
Atrogin-1 and MuRF1, as a potential biomarker 
of muscle involvement in cachexia. In BALB/c 
mice with tumor growth for 17 days, a signifi-
cant decrease was identified in mice with C26 
tumors, with an average of weight loss from 
baseline of 9.8 g (p<0.0001) (Figure 1A). In 
contrast, vehicle-treated controls gained nearly 
10% from their starting weights, illustrating a 
15-20% difference in body weight in mice with 
the C26 carcinoma, consistent with cachexia 
as previously reported [15, 18, 22]. In each of 
the six biological replicates, tumor load at 
harvest by measurement averaged 1.8 mm [3] 
(Figure 1B, Supplemental Figure 1A). No chang-
es in food or water intake were noted over the 
17 day experiment, as previously reported [15, 
18, 22].
Western analysis of diluted serum identified 
both qualitative and quantitative changes in cir-
culating Atrogin-1 (Figure 2A). Vehicle control 
animals had circulating Atrogin-1 present, as 
indicated by the black arrow in the 50 + kDa 
MW range (Figure 2A). This finding was surpris-
ing since ubiquitin ligases have not been 
described as routine circulating proteins to 
our knowledge in the healthy state. In con- 
trast, Day 17 cachexia serum exhibited a con-
sistent higher molecular weight band not seen 
in the healthy animals, indicated by the blue 
arrow (Figure 2A). Similarly, higher molecular 
weight bands were seen prominently in 4 of 
the 6 samples, including increased levels of 
molecular weight bands in the 180 + kDa 
range, highlighted by red lines to the right of the 
six lanes (Figure 2A). Densitometric analysis 
of each of samples identified a significant 
increased (p<0.05) in Atrogin-1 and its appar-
ent higher molecular bands (>2 fold) were 
present in mice with cachexia (Figure 2B). 
These additional higher molecular weight 
Atrogin-1 species made up most of the increase 
in serum Atrogin-1 seen in day 17 cachectic 
mice.
When CDF1 mice were challenged with C26 
carcinoma cells for 14 days, significant decreas-
es in final body weight, gastrocnemius weigh, 
quadriceps, heart, and fat were significantly 
decreased (Figure 3A, Supplemental Figure 
1B). Western analysis of diluted platelet-poor 
plasma (PPP) revealed the 50 + kDa MW 
Figure 1. C26 tumor cell implantation cachectic 
model characterization. A. Percentage weight change 
(loss or gain) from baseline after 17 days comparing 
vehicle control treated mice and C26 tumor implant-
ed mice (cachectic). A two-tailed Student’s t-test was 
performed to determine significance. B. Tumor load 
measurement post-17 days of vehicle (saline) or 
C26 tumor implantation. Each bar in the left graph 
represents a mouse sample; the adjacent graph 
on the right represents the mean ± SEM. N=3 (ve-
hicle controls), N=6 (C26 adenocarcinoma treated). 
*p<0.0001.
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Atrogin-1 band, indicated by a black arrow in 
Figure 3B, seen in the serum cohort (Figure 
2A). Unique higher molecular band species 
were seen in the cachexia serum samples at 
day 14, indicated by the blue arrow (Figure 3B), 
along with increases in higher molecular bands 
indicated by the blue bars (Figure 3B). Smaller 
molecular weight Atrogin-1 reactive bands were 
also seen uniquely in the cachexia serum at 14 
days, indicated by the red arrow (Figure 3B). As 
similarly found in our first experimental group, 
the density of all the Atrogin-1 bands was sig-
nificantly increased and >2 fold higher in the 
cachexia serum, compared to vehicle-treated 
controls (Figure 3C).
In separate analyses of MuRF1 in CD2F1 PPP, 
alterations in circulating MuRF1 levels were 
identified (Figure 3D). Vehicle-treated mouse 
plasma appears to have MuRF1 reactive pro-
tein species, indicated by the black arrow in 
Figure 3D. Serum from cachectic mice illustrat-
ed unique higher molecular specifies (blue 
arrow, Figure 3D) and lower molecular species 
(red arrow, Figure 3D), in addition to increased 
amounts of immunoreactive MuRF1 proteins of 
higher and low molecular weights shown by 
blue and red lines to the left of the lanes (Figure 
3D). Densitometric analysis of MuRF1 demon-
strated that cachectic mice had approximately 
three times the overall immunoreactive MuRF1 
compared to vehicle controls (Figure 3E). Us- 
ing the reagents that detected Atrogin-1 and 
MuRF1 in mouse serum and platelet poor plas-
ma, both Atrogin-1 and MuRF1 were recognized 
by immunoblot in human plasma and serum 
samples in the current study (Supplemental 
Figures 2A, 2B, 3A, 3B). In four biological 
controls, human plasma analyzed by immunob-
lot for Atrogin-1 revealed a 55 kDa band 
(Supplemental Figure 2A), paralleling the pro-
tein identified in mice (Figure 2A). Similarly, 
human plasma analyzed for MuRF1 revealed a 
single band aligning with the human heart con-
trol run in the far lane (Supplemental Figure 
2B), paralleling that found in control mice 
(Figure 3D). Immunoblot analysis of Atrogin-1 
and MuRF1 in serial dilutions of human pooled 
serum detected Atrogin-1 (Supplemental Figure 
3A) and MuRF1 (Supplemental Figure 3B) at 
the predicted molecular weights, correspond-
ing to that found in human heart lysates ran in 
Figure 2. Western blot analysis of serum Atrogin-1 in experimental cohort 1. A. Serum (1:400 diluted samples) from 
control treated mice (N=3) and C26 tumor bearing mice (cachectic) (N=6), ran with a parallel C2C12 lysate control. 
Bars in red offset the post-translational modifications of Atrogin-1. White arrow: expected molecular weight band 
for Atrogin-1. Blue arrow: represents the smallest post-translational modification identified. Red bar: highlights the 
higher molecular weight post-translational modifications identified. Black arrow: indicates the expected molecular 
weight of Atrogin-1 in C2C12 cell lysates. B. Densitometric analysis of Atrogin-1 identified significant increases in im-
munoreactive Atrogin-1 (all molecular weight species) in cachexia mouse serum compared to controls. A two-tailed 
Student’s t-test was performed to determine significance. *p<0.05.
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Figure 3. Western blot analysis of platelet poor plasma Atrogin-1 and MuRF1 in experimental cohort 2. (A) Changes 
in muscle groups (gastrocnemius (GSN), tibialis anterior, quadriceps, heart, and fat) 14 days after C26 tumor im-
plantation (top left). The average tumor load of the tumor treated mice was approximately 0.5 g (top right). (B) 
Immunoblot analysis of platelet poor plasma samples (1:400 dilution) C26 tumor bearing (cachectic) (N=6) and 
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parallel controls. Lastly, identification of the 
ubiquitously expressed carboxy terminus of 
HSP-70 interacting protein (CHIP), encoded by 
the Stub1 gene, was found to be present 
in human serum (Supplemental Figure 2C). 
A complete chemistry profile of the pooled 
serum analyzed is found in Supplemental 
Table 1.
Discussion
The ubiquitin ligases Atrogin-1 and MuRF1 are 
found specifically in striated muscle [9] and 
were first recognized for their mechanistic roles 
in skeletal muscle atrophy in 2001 [9]. The 
presence of circulating Atrogin-1 and MuRF1 in 
“healthy” blood has not previously been report-
ed, although they have been identified by ELISA 
to acute increase after myocardial infarction 
[14]. In these elegant studies, Atrogin-1 and 
MuRF1, along with 4 other cardiac and muscle-
enriched ubiquitin ligases (Rnf207, MuRF3, 
Kbtbd10/KLHL41, Asb11, and Asb2) were 
investigated in acute myocardial infarction 
patients (AMI) [14]. Of these, Atrogin-1, MuRF1, 
Rnf207, Kbtbd10/KLHL41 were significantly 
increased compared to control animals after 
experimental acute myocardial infarction in 
rats [14]. In human acute myocardial infarction 
patients, Atrogin-1 and MuRF1 were found to 
increase by 1 hour, peak at 3 hours, and 
decrease at 6-24 hours, paralleling circulating 
levels these investigators identified in experi-
mental rat surgically given an AMI [14]. Among 
the six E3s studied, the receiver operator curve 
(ROS) of the Ring Finger Protein 207 (RNF207) 
most closely compared to Troponin I sensitivity 
and specificity [14]. These studies were im- 
portant for their identification of circulating 
Atrogin-1 and MuRF1 prior to AMI since they 
had not previously been identified. Notably, the 
investigators used ELISAs to identify the levels 
of circulating E3s, so any changes in molecular 
size (e.g., post-translational modifications) were 
not identifiable by ELISA, as they were in the 
present study. Other components of the ubiqui-
tin proteasome system have been found circu-
lating, which are distinct from the 20S protea-
somes found in circulating blood cells [23], 
making it possible that circulating ubiquitin 
ligases have previously unidentified functions 
in their circulating forms.
The present study identified quantitative 
changes in the mouse of circulating immunore-
active Atrogin-1 and MuRF1 in the the C26 car-
cinoma tumor-bearing mouse model of cancer 
cachexia at 14 + days post-implantation [15, 
17, 18, 24]. The study confirmed previously 
findings that Atrogin-1 and MuRF1 circulates in 
the healthy state [14], presumably from the 
routine turnover of muscle, as seen with circu-
lating creatine kinase isoforms [25, 26]. 
However, the reason for the increased levels of 
proteins in not clear, but presumed to be sec-
ondary to inflammatory-mediated damage to 
muscle. In cancer cachexia patients, elevated 
LDH levels from myocyte damage has been 
reported [27]. Therefore, increased quantities 
of circulating Atrogin-1 and MuRF1 may be due 
to myocyte damage and release. What is most 
intriguing about the findings in the present 
study are the qualitative changes in immunore-
active Atrogin-1 and MuRF1. Specifically, the 
high molecular weight species circulating with 
cachexia are reminiscent of the mono-ubiquiti-
nation both Atrogin-1 (Figure 2A, blue arrow), 
poly-ubiquitination of Atrogin-1 (Figures 2A, 3B, 
blue lines). MuRF1 is well known to both 
mono- [28, 29] and poly-ubiquitinate different 
substrates [30]. Additionally, in cell culture, 
increased MuRF1 expression significantly 
enhanced autoubiquitination [29, 30], which 
has not been reported in vivo previously. Since 
MuRF1 forms dimers with itself [31]. it is pos-
sible that this autoubiquitination may be either 
a feedback loop or may allow communications 
between striated muscle and other organ com-
partments. The potential for other post-transla-
tional modifications beyond ubiquitin certainly 
control mice (N=3), along with a mouse heart lysate positive control. (C) Densitometric analysis of (B). (D) Immu-
noblot analysis of platelet poor plasma (1:25 dilution) from C26 tumor bearing (cachectic) (N=5) and control mice 
(N=5) and were ran with mouse heart lysate control. (E) Densitometric analysis of (D). The region of interest in each 
lane of (B and D) was performed using the rectangular image tool, with plots constructed representing peak inten-
sity in each lane, as previously described [20]. Blue arrow/blue bar: postulated post-translational modifications of 
Atrogin-1 (B) or MuRF1 (D). Black arrow: expected molecular weight band for Atrogin-1 (B) or MuRF1 (D). Red arrow/
red bar: indicates the postulated degradation products of Atrogin-1 (B) or MuRF1 (D). Densitometric analysis was 
performed on each lane and included the multiple molecular weight species (indicated by the blue, black, and red 
arrows). The densitometric values of each of these species were then added together (grouped) and statistically 
analyzed to compare the cachexia vs control groups. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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exists, and may give further insight into 
the pathophysiology of diseases, in future 
studies. 
Not only was the identification of increased 
circulating Atrogin-1 and MuRF1 seen in can- 
cer cachexia in the present study, we identi- 
fied post-translationally modified Atrogin-1 and 
MuRF1. One potential mechanism of this may 
be auto-ubiquitination, which has been shown 
in vitro when MuRF1 expression is increased in 
vitro [32, 33]. Post-translational alterations in 
proteins are important biomarkers of disease 
in use today, including the diagnosis of diabe-
tes control and rheumatoid arthritis [34-36]. In 
diabetes, elevated levels of glucose induces 
the non-enzymatic glycation of proteins, where-
by glucose reacts with amine groups to form a 
stable ketoamine Amadori Product (advanced 
glycation endproducts or AGEs) [37]. Of the gly-
cated species, hemoglobin was identified for its 
diagnostic utility due to the stability of the 
amine group added [38]. Elevated levels of 
higher molecular weight hemoglobin (A1C or 
glycated Hemoglobin) indicate poor long-term 
glucose control that cannot be detected other-
wise. Similarly, identification of proteins and pe- 
ptides post-translationally modified with citrul-
line (citrullinated) are found in rheumatoid 
arthritis. Citrullinated proteins were identified 
as autoantigens [39]. Diagnostically, they have 
been found to have the highest specificity and 
sensitivity in diagnosing RA, with high positive 
predictive value in joint destruction [40]. Post-
translational modifications of such markers 
have helped both in understanding the underly-
ing pathophysiology of disease and provide a 
useful window for disease detection and treat-
ment [41]. The role of the higher molecular 
weight Atrogin-1 and MuRF1 may have both 
roles in the pathophysiology of the systemic 
cachexia disease processes and/or may have 
diagnostic utility in future studies as diagnostic 
tests of early cachexia are generally lacking.
Current diagnostic criteria for cachexia are 
largely present much later in the pathophysiol-
ogy of disease, and include the presence of 
non-edematous weight loss >5% in <12 months 
in the presence of cancer, in addition to 3 of the 
following criteria: decreased muscle strength, 
fatigue, anorexia, low FFM indices, or abnormal 
biochemistry (increased CRP, anemia, or decr- 
eased albumin) [1]. There is little to no specific-
ity of these biochemical markers, which may or 
may not be present with cachexia [1], illustrat-
ing the need for better specific markers. Since 
early detection and disease-specific staging 
determine the outcomes of the cachectic-state 
[42], better markers of disease are needed. 
The current use of biomarkers of anemia, 
inflammation, and low albumin have been pro-
posed as markers, but do not generally identify 
cachexia until later in the pathophysiology of 
the disease, when physical symptoms can be 
obvious [7]. The occurrence/recurrence detec-
tion window is often overlooked but in patients 
undergoing cancer treatment, the earlier the 
detection, the more likely the possibility of 
impacting their prognosis [1, 43, 44].
We studied two cohorts in the present study, 
which included two different strain mouse 
strains, in addition to two methodologies of 
capturing the western blots. In cohort 1, mice 
were injected with 0.5 × 106 C26 adenocarci-
noma cells, while cohort 2 mice were injected 
with 1.0 × 106 C26 adenocarcinoma cells. The 
two doses correspond to the rapidness of the 
cachexia, with both cohort 1 and cohort 2 los-
ing ~10% weight loss, but on days 17 and 14, 
respectively. The differences in response may 
also be related to strain differences (BALB/c in 
cohort 1, CD2F1 in cohort 2) in addition to the 
differences in the doses given. The identifica-
tion of MuRF1 in mouse serum on Day 17 in 
cohort 1 was performed with serum diluted 
1:400 and the western ECL detected using 
x-ray film and up to overnight exposure (Figure 
2). In contrast, MuRF1 was detected in plasma 
only when diluted less than 1:400 (1:25 dilu-
tion) to detect western ECL using a camera-
based system (Figure 3). These differences 
are likely due to the length of exposure allowed 
in the camera vs. the x-ray film systems, or dif-
ferences in interferences in plasma vs. serum 
when detecting circulating ubiquitin ligases in 
experimental models of cancer cachexia.
This is the first time the muscle-specific atro-
gin-1 and MuRF1 ubiquitin ligases (E3) have 
been resolved on gel electrophoresis (Supple- 
mental Figures 2, 3A, 3B), illustrating the diver-
sity of molecular species (i.e., molecular weight 
forms) present. In addition to Atrogin-1 and 
MuRF1, other ubiquitously expressed E3 pro-
teins critical in protein quality control such as 
the protein CHIP are also circulating in normal 
serum (Supplemental Figure 3C), which has not 
been previously described to our knowledge. 
Given CHIP’s role in diseases such as cerebel-
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lar ataxia [45], cystic fibrosis [46-48], and car-
diac disease [49], its use diagnostically as bio-
markers may be warranted as it is for the 
Atrogin-1 and MuRF1 in cancer cachexia identi-
fied here.  
Future studies applying these findings in human 
disease should keep in mind the time-depen-
dent manner by which increased MuRF1 and 
Atrogin-1 species are found circulating in mice 
after the deliberate placement of tumor in the 
present study and objective measures of cac- 
hexia are present, including significant reduc-
tions in fat and lean body (muscle) mass by MRI 
body composition analysis [1, 15, 17, 18, 43]. 
The experimental design here did seek to iden-
tify the earliest time points that increases in 
MuRF1 and Atrogin-1 are detectable, which 
would be a critical point in investigating these 
markers in patients with suspected or estab-
lished cachexia. This is a particularly challeng-
ing issue in studying human cachexia as de- 
tection of cachexia by MRI is not routinely per-
formed and pragmatically is diagnosed at later 
time points where weight loss is visually detect-
able. The type of cancer and progression is also 
an important variable that will need to be taken 
into account when correlating these biomark-
ers with the progression and timing of disease 
occurrence/recurrence.
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Supplemental Figure 1. Weight changes in control and tumor implanted mice at harvest. A. Weight change as a 
percent in individual mice as a percentage of their own baseline weights at day 17 in cohort 1. B. Weight change in 
individual mice in grams compared to their own baseline weights at day 14 in cohort 2. Cohort 1: N=3 vehicle con-
trol treated mice; N=6 C26 tumor treated mice. Cohort 2: N=5 vehicle control treated mice; N=5 C26 tumor treated 
mice. A two-tailed Student’s t-test was performed to determine significance. *p<0.05.
Supplemental Figure 2. Immunoblot analysis of control human plasma samples. Identification of (A). Atrogin-1 or 
(B). MuRF1 in human plasma. Black arrow: Indicates molecular weight of expected protein. N=4 biological repli-
cates.
Supplemental Figure 3. Immunoblot analysis of pooled human control serum for (A) Atrogin-1, (B) MuRF1, or (C) 
CHIP (Stub1). Black arrow: Indicates molecular weight of expected protein. Parallel clinical chemistry of the pooled 
samples can be found in Supplemental Table 1.
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Supplemental Table 1. Basic clinical chemistry profile of the human pool-21 used in the present study 
(Supplemental Figure 3, immunoblot studies on serum dilutions). UNC Hospitals Core (Chemistry) 
Laboratory anonymous serum pool
Chemistry Analyte POOL-21 
Value
Reference Range Analyzer Used
Albumin 3.26 3.5-5.0 g/dL Advia (FSN-1)
Alkaline phosphatase* 146.5 38-126 U/L Advia (FSN-1)
Alanine Aminotransferase (ALT)* 59.1 Male: 19-72 U/L; Female: 15-48 U/L Advia (FSN-1)
Amylase 56 30-100 Advia (FSN-1)
Aspartate Aminotransferase (AST)* 77.9 Male: 19-55; Female: 14-38 Advia (FSN-1)
Bilirubin (Conjugated) 0 ≤0.1 mg/dL Advia (FSN-1)
Bilirubin (Unconjugated) 0.47 ≤1.2 mg/dL Advia (FSN-1)
Blood urea nitrogen (BUN) 19.7 7-21 mg/dL Advia (FSN-1)
C3 (Complement C3) 140.81 88-171 mg/dL Advia (FSN-1)
C4 (Complement C4) 29.86 15-48 mg/dL Advia (FSN-1)
Calcium (Ca2+) 8.85 8.5-10.2 mg/dL Advia (FSN-1)
Cholesterol 150.3 <200 mg/dL Advia (FSN-1)
Creatine Kinase* 228.7 145 U/L Advia (FSN-1)
Chloride 106.4 98-107 mmol/L Advia (FSN-1)
Bicarbonate (CO2) 22.2 22-30 mmol/L Advia (FSN-1)
Creatine 1.39 Male: 0.8-1.4; Female: 0.7-1.1 Advia (FSN-1)
C-Reactive Protein (hs)* 4.5 1.0-3.0 mg/L Advia (FSN-1)
Serum Ferritin (Iron)* 67.3 35-165 ug/dL Advia (FSN-1)
Glucose (Non-fasting) 118.2 65-179 mg/dL Advia (FSN-1)
HDL Cholesterol 44 40-59 mg/dL Advia (FSN-1)
Total IgA 254.81 40-400 mg/dL Advia (FSN-1)
Total IgG 1086.9 600-1700 mg/dL Advia (FSN-1)
Total IgM 96.76 35-290 mg/dL Advia (FSN-1)
Potassium (K+) 4.23 3.5-5.0 mmol/L Advia (FSN-1)
Lactate Dehydrogenase* 670.4 338-610 U/L Advia (FSN-1)
Lipase 182 44-232 U/L Advia (FSN-1)
Magnesium (Mg2+) 1.89 1.6-2.2 mg/dL Advia (FSN-1)
Sodium (Na+) 138.8 135-145 mmol/dL Advia (FSN-1)
Rheumatoid Factor 10.2 0.0-15.0 U/ml Advia (FSN-1)
Total Bilirubin 0.77 ≤1.2 mg/dL Advia (FSN-1)
Total Protein** 6.23 6.6-8.0 g/dL Advia (FSN-1)
Triglyceride* 150.1 <150 mg/dL Advia (FSN-1)
Transthyretin (TTR) 21.67 17-34 mg/dL Advia (FSN-1)
Uric acid 5.1 Male: 4.0-9.0; Female: 3.0-6.5 Advia (FSN-1)
Thyroxine (Total T4) 7.31 5.5-11.0 ug/dL VitrosECiQ (Eci#1, #3)
Free T4 (FT4)* 1.42 0.71-1.4 ng/dL VitrosECiQ (Eci#1, #3)
Triiodothyonine (T3) 1.11 1.0-1.7 ng/mL VitrosECiQ (Eci#1, #3)
Follicle Stimulating Hormone (FSH) 13.4 Male: 1.6-9.7 mIU/mL
Female: Follicular phase: 1.9-11.6 mIU/mL
Luteal phase: 1.4-9.6 mIU/mL
Post Menopausal: 21.5-131.0 mIU/mL
VitrosECiQ (Eci#1, #3)
Leuteinizing Hormone (LH) 6.54 Male: 3.0-10.0 mIU/mL
Female: Follicular phase: 2.6-12.1 mIU/mL
Luteal phase: 0.8-15.5 mIU/mL
Post Menopausal: 13.1-86.5 mIU/mL
VitrosECiQ (Eci#1, #3)
Prolactin 23.6 5-19 ng/mL VitrosECiQ (Eci#1, #3)
Ferritin* 629 Male: 27-377 ng/mL; Female: 3-151 VitrosECiQ (Eci#1, #3)
Folate 14.4 >2.7 ng/mL VitrosECiQ (Eci#1, #3)
Prostate Specific Antigen (PSA) 1.76 <4 ng/mL VitrosECiQ (Eci#1, #3)
CA-125 59.9 0.0-34.9 U/mL VitrosECiQ (Eci#1, #3)
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Carcinoembryonic Antigen (CEA)* 4.23 0-3.0 ng/mL VitrosECiQ (Eci#1, #3)
Estradiol (E2) 349.4 Male: 5-66pg/mL
Female (Postmenopausal): 5-38 pg/mL
Female (Ovulating): Follicular phase 27-161pg/mL
Periovulatory: 187-382 pg/mL
Luteal phase: 33-201 pg/mL
VitrosECiQ (Eci#1, #3)
Progesterone 2.68 Male: <1.00 ng/mL
Female: Follicular phase: <1.70 ng/mL
Luteal phase: 1.00-22.40 ng/mL
Post Menopausal: <1.00 ng/mL
VitrosECiQ (Eci#1, #3)
Cortisol 19.1 Before 10:00am: 4.5-22.7 µg/dL
After 5:00pm: 1.7-14.1 µg/dL
Critical: <1.5 µg/dL
VitrosECiQ (Eci#1, #3)
Testosterone 74 Male >20 yrs of age: 179-756 ng/dL
Female with normal menstrual cycle: 6-77 ng/dL
VitrosECiQ (Eci#1, #3)
Parathyroid Hormone 53.78 12-72 pg/mL Roche Elecsys (Elecsys #1)
CK-MB 4.82 0-6.0 ng/mL Roche Elecsys (Elecsys #1)
Troponin T* 0.056 0.000-0.029 Roche Elecsys (Elecsys #1)
NT-proBNP* 3123 Male: 0-177; Female: 0-226 Roche Elecsys (Elecsys #1)
βHCG* 734.7 Non-pregnant: <5 mIU/mL (U/L) Roche Elecsys (Elecsys #1)
Serum hCG increases with age in non-pregnant 
women. A cutoff of 14.0 IU/L should be used 
when interpreting hCG results in women >55 yrs. 
Pregnancy is unlikely in perimenopausal women 
41-55 yrs with an hCG between 5.0 and 14.0 IU/L 
if serum FSH is >20.0IU/L. Clin Chem 2005; 51: 
1830-5
WksPreg Mean Range n
4 1110 40-4480 42
5 8050 270-28700 52
6 29700 3700-84900 67
7 58800 9700-120000 62
8 79500 31000-184000 37
9 91500 61200-152000 25
10 71000 22000-143000 12
14 33100 14300-75800 219
15 27500 12300-60300 355
16 21900 8800-54500 163
17 18000 8100-51300 68
18 18400 3900-49400 30
19 20900 3600-56600 14
*Above reference range; **Below reference range. Analysis for * and ** did not include gender-specific cut-off ranges not applicable to pooled 
serum.
